4,5-二苯基-2-咪唑硫醇 | 2349-58-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硫醇盐
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4,5-二苯基-2-咪唑硫醇
• 英文名称: 2-mercapto-4,5-diphenylimidazole
• 英文别名: 4,5-diphenyl-1H-imidazole-2-thiol；4,5-diphenyl-1,3-dihydroimidazole-2-thione
• CAS: 2349-58-8
• 化学式: C₁₅H₁₂N₂S
• mdl: MFCD00005189
• 分子量: 252.34
• InChiKey: GMTAWLUJHGIUPU-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C (lit.)
• 沸点：
  407.5±55.0 °C(Predicted)
• 密度：
  1.1917 (rough estimate)
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与不相容的材料接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.2
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  2933290090
• 储存条件：
  密封储存，应存放在阴凉干燥的库房中。

SDS

Name:	4 5-Diphenyl-2-Imidazolethiol 97% Material Safety Data Sheet
Synonym:	None known
CAS:	2349-58-8

Section 1 - Chemical Product MSDS Name:4 5-Diphenyl-2-Imidazolethiol 97% Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2349-58-8	4,5-Diphenyl-2-Imidazolethiol	97	219-077-9

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2349-58-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: slightly yellow
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: > 300 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H12N2S
Molecular Weight: 252.33

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, irritating and toxic fumes and gases, carbon dioxide, hydrogen sulfide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2349-58-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4,5-Diphenyl-2-Imidazolethiol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 2349-58-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2349-58-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2349-58-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,5-二苯基-2-咪唑硫醇 在 sodium hydroxide 、 乙酸酐 、 potassium carbonate 、 一水合肼 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 17.33h， 生成 Ethyl ((5-(1-((4,5-diphenyl-1H-imidazol-2-yl)thio)-2-methylpropyl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate
  参考文献：
  名称：

  Gursoy; Demirayak; Cesur, Pharmazie, 1990, vol. 45, # 4, p. 246 - 250

  摘要：

  DOI：
• 作为产物：
  描述：

  diphenyl-4,5-thioxo-2-imidazoline 在 sulfur 作用下， 反应 1.0h， 以75%的产率得到4,5-二苯基-2-咪唑硫醇
  参考文献：
  名称：

  Hammouda, Hamdy Ali; Abd-Allah, Sanaa Osman; Zoorob, Hanafi Hassan, Acta Chimica Hungarica, 1985, vol. 119, # 1, p. 49 - 56

  摘要：

  DOI：
• 作为试剂：
  描述：

  5-bromo-N-heptylpentanamide 、 4,5-二苯基-2-咪唑硫醇 在 4,5-二苯基-2-咪唑硫醇 作用下， 以63的产率得到5-<(4,5-diphenyl-1H-imidazol-2-yl)thio>-N-heptylpentanamide
  参考文献：
  名称：

  J. Med. Chem. 1994, 37, 3511-3522

  摘要：

  DOI：

文献信息

• Antiinflammatory imidazole derivatives
  申请人：Schering Aktiengesellschaft

  公开号：US04402960A1

  公开（公告）日：1983-09-06

  Imidazole derivatives of the formula ##STR1## wherein AR.sub.1 and AR.sub.2 each independently is phenyl, optionally substituted by halogen atoms, alkyl residues, alkoxy residues; or dialkylamino residues; pyridyl, furyl; or thienyl; R.sub.1 is hydrogen; alkyl of 1-6 carbon atoms optionally substituted by hydroxy groups, alkoxy groups, or acyloxy groups; benzyl; tetrahydropyran-2-yl; or tetrahydrofuran-2-yl; n is 0, 1 or 2; and Z is phenyl optionally substituted by halogen atoms, alkyl groups, alkoxy groups, nitro groups, amino, acylamino groups or trifluoromethyl groups; pyridyl; N-oxypyridyl; pyrimidinyl; thiazolyl; or thienyl, and the physiologically acceptable salts thereof with acids, have valuable pharmacological activity, e.g., antiinflammatory activity.

  咪唑衍生物的化学式为##STR1##其中AR.sub.1和AR.sub.2各自独立地是苯基，可以选择地被卤原子，烷基残基，烷氧基残基; 或二烷基氨基残基; 吡啶基，呋喃基; 或噻吩基; R.sub.1是氢; 1-6个碳原子的烷基，可以选择地被羟基，烷氧基或酰氧基取代; 苄基; 四氢吡喃-2-基; 或四氢呋喃-2-基; n为0, 1或2; Z是苯基，可以选择地被卤原子，烷基，烷氧基，硝基，氨基，酰胺基或三氟甲基取代; 吡啶基; N-氧基吡啶基; 嘧啶基; 噻唑基; 或噻吩基，以及其与酸形成的生理上可接受的盐具有有价值的药理活性，例如抗炎活性。
• N-Heterocyclic Carbene-Catalyzed <i>in situ</i> Activation of Alkynyl Acids for C−S Bond Formation: Access to Imidazo[2,1-<i>b</i> ][1,3]thiazinones
  作者：Kewen Sun、Shiyi Jin、Jindong Zhu、Xinmiao Zhang、Maoyu Gao、Wanqi Zhang、Tao Lu、Ding Du

  DOI：10.1002/adsc.201800857

  日期：2018.12.3

  Alkynyl acids are first utilized as alkynyl acylazolium precursors through an in situ activation strategy for the efficient construction of carbon‐sulfur bond in a formal [3+3] annulation. This protocol offers a direct and rapid pathway for the synthesis of imidazo[2,1‐b][1,3]thiazinone skeleton, a useful heterocyclic class frequently found in many bioactive compounds. This reaction also has the advantages

  炔酸首先通过原位活化策略用作炔基酰基la唑前体，以便在正式​​的[3 + 3]环空中有效构建碳硫键。该方案为合成咪唑并[2,1– b ] [1,3]噻嗪酮骨架提供了直接而快速的途径，该骨架是在许多生物活性化合物中经常发现的有用的杂环类。该反应还具有可扩展性，易于获得的材料以及在露天中易于操作的优点。
• Tandem Double-Cross-Coupling/Hydrothiolation Reaction of 2-Sulfenyl Benzimidazoles with Boronic Acids
  作者：Alexandra Basilio Lopes、Mickael Choury、Patrick Wagner、Mihaela Gulea

  DOI：10.1021/acs.orglett.9b02067

  日期：2019.8.2

  tandem palladium-catalyzed reaction involving a Suzuki–Miyaura coupling, a desulfenylative coupling, and a hydrothiolation of a triple bond is reported. Notably, the desulfenylative coupling occurs without copper(I) assistance and the hydrothiolation is totally regioselective and stereoselective. The overall process results in the double incorporation of the boronic acid and the reincorporation of

  据报道，一种新的串联钯催化的反应涉及Suzuki-Miyaura偶联，脱硫基偶联和三键的氢硫基化。值得注意的是，在没有铜（I）辅助的情况下发生了脱硫基偶联，并且氢硫基化是完全区域选择性和立体选择性的。整个过程导致硼酸的两次掺入和亚硫基部分的再掺入到产物结构中。从2-（溴苄基亚硫基）-1-炔丙基苯并咪唑开始，该转化导致带有立体定义的烯基硫的各种取代的苯并咪唑。
• Use of imidazoles for the treatment of atherosclerosis
  申请人：Du Pont Merck Pharmaceutical Company

  公开号：US05166214A1

  公开（公告）日：1992-11-24

  This invention relates to imidazoles as inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT), processes for their preparation, and their use as antihypercholesterolemic agents or antiatherosclerotic. The compounds for use in the described method are compounds of Formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are selected independently from H, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.7 -C.sub.14 araalkyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.8 branched alkyl, CH.sub.3 S(O).sub.r, NO.sub.2, CF.sub.3, or NR.sup.7 R.sup.8 ; R.sup.3 is H, C.sub.1 -C.sub.6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH.sub.3, CH.sub.3 O, or CF.sub.3 ; R.sup.4 is straight chain C.sub.1 -C.sub.8 alkyl optionally substituted with F; C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.7 -C.sub.14 aralkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8, or NCOR.sup.7 ; C.sub.3 -C.sub.6 alkenyl or alkynyl, C.sub.1 -C.sub.3 perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.1 -C.sub.4, alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8 or NCOR.sup.7 ; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8, or NCOR.sup.7 ; 2-, 3-, or 4- or pyrindinyl, pyrimidinyl, or biphenyl; R.sup.5 is H, C.sub.1 -C.sub.6 alkyl, or benzyl; R.sup.6 is C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.8 alkenyl of alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8, or NCOR.sup.7 ; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8, or NCOR.sup.7 ; R.sup.7 and R.sup.8 are selected independently from H or C.sub.1 -C.sub.4 alkyl; A is C.sub.2 -C.sub.10 alkyl, C.sub.3 -C.sub.10 branched alkyl, C.sub.3 -C.sub.10 alkenyl, or C.sub.3 -C.sub.10 alkynyl; Y is O; Z is NHR.sup.4, OR.sup.4, or R.sup.4 ; r is 0-2, or a pharmaceutically acceptable salt thereof.

  这项发明涉及咪唑作为酰基辅酶A：胆固醇酰基转移酶（ACAT）的抑制剂，其制备方法以及它们作为抗高胆固醇药物或抗动脉粥样硬化药物的用途。所述方法中用于的化合物为式（I）的化合物：##STR1## 其中R.sup.1和R.sup.2分别选择自H，C.sub.1 -C.sub.8烷基，C.sub.3 -C.sub.8支链烷基，C.sub.3 -C.sub.7环烷基，C.sub.4 -C.sub.10环烷基烷基，C.sub.7 -C.sub.14芳基烷基，苯基，可选择地取代为1至3个来自F，Cl，Br，OH，C.sub.1 -C.sub.4烷氧基，C.sub.1 -C.sub.4烷基，C.sub.3 -C.sub.8支链烷基，CH.sub.3S（O）.sub.r，NO.sub.2，CF.sub.3或NR.sup.7R.sup.8的基团；R.sup.3为H，C.sub.1 -C.sub.6烷基，烯丙基，苄基，或可选择地取代为F，Cl，CH.sub.3，CH.sub.3O或CF.sub.3的苯基；R.sup.4为直链C.sub.1 -C.sub.8烷基，可选择地取代为F；C.sub.3 -C.sub.8支链烷基，C.sub.3 -C.sub.7环烷基，C.sub.4 -C.sub.10环烷基烷基，C.sub.7 -C.sub.14芳基烷基，其中芳基可选择地取代为1至3个来自C.sub.1 -C.sub.4烷基或烷氧基，F，Br，Cl，NH.sub.2，OH，CN，CO.sub.2H，CF.sub.3，NO.sub.2，C.sub.1 -C.sub.4羧烷氧基，NR.sup.7R.sup.8，或NCOR.sup.7；C.sub.3 -C.sub.6烯基或炔基，C.sub.1 -C.sub.3全氟烷基，苯基，可选择地取代为1至3个来自C.sub.1 -C.sub.4烷基，C.sub.3 -C.sub.8支链烷基，C.sub.1 -C.sub.4烷氧基，F，Br，Cl，NH.sub.2，OH，CN，CO.sub.2H，CF.sub.3，NO.sub.2，C.sub.1 -C.sub.4羧烷氧基，NR.sup.7R.sup.8或NCOR.sup.7；五氟苯基，苄基，可选择地取代为1至3个来自C.sub.1 -C.sub.4烷基或烷氧基，F，Br，Cl，NH.sub.2，OH，CN，CO.sub.2H，CF.sub.3，NO.sub.2，C.sub.1 -C.sub.4羧烷氧基，NR.sup.7R.sup.8，或NCOR.sup.7；2-，3-，或4-或吡啶基，嘧啶基，或联苯基；R.sup.5为H，C.sub.1 -C.sub.6烷基，或苄基；R.sup.6为C.sub.1 -C.sub.8烷基，C.sub.3 -C.sub.8支链烷基，C.sub.3 -C.sub.7环烷基，C.sub.3 -C.sub.8烯基或炔基，苯基，可选择地取代为1至3个来自C.sub.1 -C.sub.4烷基或烷氧基，F，Br，Cl，NH.sub.2，OH，CN，CO.sub.2H，CF.sub.3，NO.sub.2，C.sub.1 -C.sub.4羧烷氧基，NR.sup.7R.sup.8，或NCOR.sup.7；五氟苯基，苄基，可选择地取代为1至3个来自C.sub.1 -C.sub.4烷基或烷氧基，F，Br，Cl，NH.sub.2，OH，CN，CO.sub.2H，CF.sub.3，NO.sub.2，C.sub.1 -C.sub.4羧烷氧基，NR.sup.7R.sup.8，或NCOR.sup.7；R.sup.7和R.sup.8分别选择自H或C.sub.1 -C.sub.4烷基；A为C.sub.2 -C.sub.10烷基，C.sub.3 -C.sub.10支链烷基，C.sub.3 -C.sub.10烯基，或C.sub.3 -C.sub.10炔基；Y为O；Z为NHR.sup.4，OR.sup.4，或R.sup.4；r为0-2，或其药用盐。
• Copper-Mediated Tandem C(<i>sp</i>²)-H Sulfenylation and Annulation of Arenes with 2-Mercaptoimidazoles: Regio- and Site-selective Access to Polycyclic Fused Imidazo[2,1-<i>b</i>][1,3]thiazinones
  作者：Jidan Liu、Zixi Xue、Zhizhao Zeng、Yi-xin Chen、Guoshu Chen

  DOI：10.1002/adsc.201600775

  日期：2016.12.7

  by C(sp2)–H thiolation of benzamide with 2‐mercaptoimidazole followed by intramolecular nucleophilic substitution of the amide carbonyl group. A notable feature of this reaction is that it can afford rather complex products in a single synthesis step from easily accessible starting materials using amide‐oxazoline as a removable bidentate directing group. A variety of benzamides and 2‐mercaptoimidazoles

  已经开发出有效的铜介导的串联C（sp 2）–H磺酰基化和芳烃与2-巯基咪唑环化的方法，以提供多环稠合的咪唑并[2,1– b ] [1,3]噻嗪酮。串联反应可能是由苯甲酰胺与2-巯基咪唑的C（sp 2）–H硫代化，然后是酰胺羰基的分子内亲核取代引起的。该反应的显着特征是，它可以使用酰胺-恶唑啉作为可移动的双齿导向基团，从易于获得的起始原料在单个合成步骤中获得相当复杂的产物。带有不同取代基的各种苯甲酰胺和2-巯基咪唑均适用于这种转化。

表征谱图